Cover Image

Rectal Ozone therapy role in the quality of life of a Heart Failure patient.


Abstract


Heart Failure (HF) is a nosological entity with multiple pathophysiological aspects including the phenomenon of Ischemia-Reperfusion (I/R) 6. It is reported to be a heterogeneous syndrome resulting from structural damage to the myocardial fiber which occurs through various mechanisms. On the other hand, ozone therapy has shown a protective role against I/R phenomenon observed in clinical situations such as HF and circulatory shock. On this point, our objective was to evaluate rectal ozone therapy effect in a patient with decompensated heart failure and diabetes mellitus type 2, treated at our Cardiozono Medical Center, in Luanda, Angola.
Variables to be measured before and after rectal ozone therapy were: functional classification, biochemical parameters and left ventricular ejection fraction. As a result, rectal ozone therapy was able to improve the clinical condition of our patient, the renal and hepatic function tests were also improved and the ejection fraction of the left ventricle was significantly increased. As a conclusion we have that rectal ozone therapy, complementary to conventional treatment, improved the quality of life of this patient, as well as, the ejection fraction of the left ventricle was significantly increased, reflecting the cardioprotective effect of rectal ozone therapy.

Keywords


Heart failure, phenomenon of ischemia reperfusion, rectal ozone therapy, ejection fraction of the left ventricle.

Full Text:

PDF

References


  1. Menendez S, Gonzalez R, Ledea OE, Hernandez F, León OS, Daaz MF. El ozono: aspectos básicos y aplicaciones clínicas [Ozone: basics and clinical applications]. La Habana: Ed. CENIC; 2008. 207 p. Spanish. Available from: https://www.researchgate.net/publication/260834437.

  2. Calunga JL, Bello M, Chaple M, Barber E, Menendez S, Merino N. Ozonoterapia en la glomerulonefritis tóxica experimental por adriamicina [Ozone therapy in experimental toxic adriamycin glomerulonephritis]. Rev Cubana Invest Biomed. 2004 Sep;23(3):139-143. Spanish. Available from: http://scielo.sld.cu/pdf/ibi/v23n3/ibi02304.pdf.

  3. Bocci V, Borrelli E, Travagli V, Zanardi I. The Ozone Paradox: Ozone Is a Strong Oxidant as Well as a Medical Drug. Med Res Rev. 2009;29(4):646-682. doi:10.1002/med.20150.

  4. Calunga JL, Trujillo Y, Menéndez S, Zamora Z, Alonso Y, Merino M, et al. Ozone oxidative post-conditioning in acute renal failure. JPP. 2009 Feb;61(2):221-227. doi:10.1211/jpp/61.02.0012.

  5. Ajamieh HH, Berlanga J, Merino N, Sánchez GM, Carmona AM, Cepero CM, et al. Role of protein synthesis in the protection conferred by ozone-oxidative-preconditioning in hepatic ischaemia/reperfusion. Transpl Int. 2005 May;18(5):604-612. doi:10.1111/j.1432-2277.2005.00101.x.

  6. Ruiz M, García D. Fisiopatología del daño miocárdico por isquemia-reperfusión: nuevas oportunidades terapéuticas en el infarto agudo de miocardio [Pathophysiology of myocardial damage due to ischemia-reperfusion: new therapeutic opportunities in acute myocardial infarction]. Rev Esp Cardiol. 2009;62(2):199-209. Spanish. doi:10.1016/S0300-8932(09)70162-9.

  7. Mendez A. Fisiopatologia de la insuficiencia cardiaca [Pathophysiology of heart failure]. Arch Cardiol Mex. 2006 Supl.2/Apr-Jun;76:182-187. Spanish. Available from: http://www.scielo.org.mx/pdf/acm/v76s2/v76s2a25.pdf.

  8. Borroto V, Suarez LR, Bocci V, Lima LB, Cambara R, Lima S. Ozonoterapia en la insuficiencia cardiaca cronica [Ozone therapy in chronic heart failure]. Rev Esp Ozonoter. 2016;6(1):9-26. Spanish. Available from: http://www.xn- revistaespañolaozonoterapia-7xc.es.

  9. Cespedes J, Martin Y, Carballosa MR, Dager DR. Clinical study of patients with heart failure under treatment with ozone therapy. J Ozone Ther. 2018;2(3):1-6. doi:10.7203/jo3t.2.3.2018.11461.

  10. Barrios V, Peña G, Gonzalez JR, Alegria E, Lozano JV, Llisterri JL, Gonzalez I. Hipertensión arterial e insuficiencia cardiaca en las consultas de Atención Primaria y de Cardiología en España [Arterial hypertension and heart failure in Primary Care and Cardiology consultations in Spain]. Rev Clin Esp. 2003;203(7):334-342. Spanish. Available from: https://www.revclinesp.es/es-hipertension-arterial-e-insuficiencia-cardiaca-articulo-13047947.

  11. Neria E, Rivero A, Patiño E. Fracción de eyección y acortamiento por ecocardiograma como probables marcadores de enterocolitis necrotizante en prematuros [Ejection fraction and shortening by echocardiography as probable markers of necrotizing enterocolitis in premature infants]. An Med (Mex). 2010 Abril-junio;55(2):71-78. Spanish. Available from: https://www.medigraphic.com/pdfs/abc/bc-2010/bc102d.pdf.

  12. Wang Z, Zhang A, Meng W, Wang T, Li D, Liu Z, Liu H. Ozone protects the rat lung from ischemia-reperfusion injury by attenuating NLRP3-mediated inflammation, enhancing Nrf2 antioxidant activity and inhibiting apoptosis. Eur J Pharmacol. 2018 Sep;15(835):82-93. doi:10.1016/j.ejphar.2018.07.059.

  13. Calunga JL, Arenas B, Leon R, Lastre R, Wilkins I, Nuñez CR. Presentación de un caso de pie diabético neuro-infeccioso tratado con ozonoterapia [Presentation of a case of a neuro-infectious diabetic foot treated with ozone therapy]. Rev CENIC Cienc Biol. 2018 Abril;46(2):195-202. Spanish. Available from: https://revista.cnic.edu.cu/index.php/RevBiol/article/view/89/89.

  14. Schwartz A, Rivera HG, Talbott B. Ozone therapy in the treatment of the neuroinfectious diabetic foot. Case report. Ozone Therapy Global Journal. 2019;9(1):125-133. Available from: https://dialnet.unirioja.es/descarga/articulo/7306849.pdf.

  15. Castro-Gerónimo VD, García-Rodríguez RV, Diosdado-Contreras M, et al. Oxidative stress and inflammation in heart attack: Keys to cardiac remodeling. Rev Biomed. 2022;33(1):33-43.

  16. Calunga-Fernandez JL, Menendez-Cepero S, Zamora-Rodriguez Z: Ozone therapy on rats submitted to subtotal nephrectomy: role of interleukin 6 and antioxidant system. Revista Cubana de Investigaciones Biomédicas. 2019;38(1):10-19.

  17. Meng W, Xu Y, Li D, Zhu E, Deng L, Liu Z, Zhang G, Liu H. Ozone protects rat heart against ischemia-reperfusion injury: A role for oxidative preconditioning in attenuating mitochondrial injury. Biomed Pharmacother. 2017;88:1090-1097. doi:10.1016/j.biopha.2017.01.151.

  18. Galie M, Covi V, Tabaracci G, Malatesta M. The role of Nrf2 in the antioxidant cellular response to medical ozone exposure. Int J Mol Sci. 2019 Aug;20(16):40-09. doi:10.3390/ijms20164009.

  19. Baialardo AG. Síndrome cardio-hepático ¿Qué debemos saber cómo cardiólogos? [Cardio-hepatic syndrome What should we know as cardiologists?] Insuf Card. 2015;10(2):66-77. Spanish. Available from: http://www.insuficienciacardiaca.org/pdf/v10n2_15/v10n2a03.pdf.

  20. Zamora Z, Borrego A, Lopez OY, Delgado R, Gonzalez R, Menendez S, Hernandez F, et al. Effects of ozone oxidative preconditioning on TNFalfa release and antioxidant prooxidant intracellular balance in mice during endotoxic shock. Mediator Inflamm. 2005;1:16–22. doi:10.1155/MI.2005.16.

  21. Chen H, Xing B, Liu X, Zhan B, Zhou J, Zhu H, et al. Ozone oxidative preconditioning inhibits inflammation and apoptosis in a rat model of renal ischemia/reperfusion injury. Eur J Pharmacol. 2008 Mar; 10;581(3):306-314. doi:10.1016/j.ejphr.2007.11.050.


Refbacks

  • There are currently no refbacks.